Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

FDA Approval Sought for Ivosidenib in Previously Treated IDH1-Mutant Cholangiocarcinoma

March 1st 2021

A supplemental new drug application has been submitted to the FDA for ivosidenib tablets as a potential therapeutic option for patients with previously treated, IDH1-mutated cholangiocarcinoma.

Personalized Radioembolization Improves OS Vs Standard Dosing in Advanced HCC

March 1st 2021

Yttrium-90 glass microspheres administered in a personalized, dosimetric approach demonstrated a 16-month improvement in overall survival compared with a standard dosimetric approach in patients with unresectable hepatocellular carcinoma.

Cholangiocarcinoma: Appropriate Diagnostic Work-Up

March 1st 2021

Types of assessments that are used to help appropriately work up a patient suspected of having a bile duct cancer.

Rising Incidence of Cholangiocarcinoma

March 1st 2021

Factors that may contribute to the rise in the number of cholangiocarcinoma cases being reported, as suggested by GI oncologists.

Bekaii-Saab Shares Suggested Sequencing Algorithm for Advanced HCC

February 26th 2021

Tanios S. Bekaii-Saab, MD, FACP, shares his approach for treating patients with HCC across several lines of therapy, as well as factors to consider when making sequencing decisions.

Grothey Spotlights the Growing HER2+ Paradigm in GI Cancers

February 25th 2021

Axel Grothey, MD, discusses the excitement surrounding HER2-directed therapies in gastrointestinal malignancies, the approval of trastuzumab deruxtecan in HER2-positive metastatic gastric/gastroesophageal junction cancer, and the investigational agents patritumab deruxtecan and zanidatamab that are poised to further advance the paradigm.

Practical Considerations of TACE in HCC

February 25th 2021

A panel of experts discuss practical considerations for TACE in patients with unresectable BCLC stage B HCC, as well as define TACE-refractoriness and what to do if a patient fails treatment.

Management Challenges of Advanced HCC

February 25th 2021

Richard S. Finn, MD, leads a panel of experts in a discussion around key updates from the 2021 ASCO GI virtual meeting, and a review of the rapidly evolving landscape for unresectable advanced hepatocellular carcinoma.

Findings Suggest Cholesterol Plays a Surprising Role in Pancreatic Cancer

February 24th 2021

Although a majority of pancreatic cancer cells are highly dependent on endogenous biosynthesis of cholesterol, new research from investigators at Fox Chase Cancer Center has demonstrated that some more aggressive pancreatic cancers are completely independent of this process.

First-line Locoregional Therapies in Advanced HCC

February 24th 2021

Amit Singal, MD, MS, and Masatoshi Kudo, MD, PhD, discuss the benefit/risk ratio of first-line locoregional therapies in advanced hepatocellular carcinoma.

Challenges in the Management of Advanced HCC

February 24th 2021

Amit Singal, MD, MS, reviews challenges in the management of advanced hepatocellular carcinoma (HCC).

Dr. Hubbard on Detecting Disease Progression in CRC

February 23rd 2021

Joleen M. Hubbard, MD, discusses identifying disease progression in patients with colorectal cancer.

Investigators Aim Novel T-Cell Therapy at Solid Tumor Target

February 23rd 2021

ADP-A2M4CD8, a novel T-cell therapy, is being investigated in a range of tumor types that express MAGEA4, an antigen expressed in solid tumors that investigators say represents a promising target for cellular immunotherapy.

Heterogeneous Nature of Cholangiocarcinoma

February 22nd 2021

GI oncologists explain the complicated nature of cholangiocarcinoma as it relates to the disease’s underlying pathogenesis.

Cholangiocarcinoma Described

February 22nd 2021

Dr Sameek Roychowdhury, of the James Cancer Hospital Solove Research Institute, describes what cholangiocarcinoma is, specifically highlighting how the disease often presents in patients.

New Applications for Chemotherapy, PARP Inhibitors Drive Progress in Pancreatic Cancer

February 21st 2021

Although chemotherapy remains the cornerstone of treatment in pancreatic ductal adenocarcinoma, the field has begun to carve out more personalized approaches evidenced by the POLO trial.

Cologuard mt-sDNA Test Could Provide a Noninvasive Screening Option for CRC

February 19th 2021

February 19, 2021 - Multitarget stool DNA test Cologuard could present a potential noninvasive screening method for colorectal cancer, as it has demonstrated high specificity among average-risk patients aged 45 to 49 years.

Nanoliposomal Irinotecan Possesses Potential to Shake Up Pancreatic Cancer Paradigm

February 19th 2021

Reema A. Patel, MD, discusses the potential for nanoliposomal irinotecan in pancreatic cancer and other emerging approaches under exploration.

Dr. Mody on Progress Made With Y-90 in Hepatocellular Carcinoma

February 18th 2021

Kabir Mody, MD discusses new directions with yttrium-90 glass microspheres in hepatocellular carcinoma as demonstrated in the retrospective LEGACY study.

Pamrevlumab May Address Unmet Need for Locally Advanced Pancreatic Cancer

February 17th 2021

February 17, 2021 – Pamrevlumab, a first-in-class inhibitor of connective tissue growth factor activity, is being evaluated in combination with gemcitabine and nab-paclitaxel (Abraxane) in a phase 3 trial for patients with unresectable locally advanced pancreatic cancer, a population in need of new options.